Organization (Academic)
Seoul National University
ClinicalTrials.gov lists Seoul National University as lead sponsor of 2,306 trials, counting the companies grouped under it. Seoul National University itself has 16 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 5 in 2026 and about 4 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 5 already registered with a 2026 start date: at the cutoff, 1 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
Logo Original raster image was excerpted from the source file, as specified above. Vectorized by the user User:Nudimmud ., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Seoul National University and 4 companies grouped under it: 2,306 lead-sponsored trials (31 its own, 2,275 in the grouped companies) and 5 legal-entity registrations (1 its own, 4 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (4)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Seoul National University Hospital | 1,896 | 1 |
| Seoul National University Bundang Hospital | 376 | 1 |
| Seoul National University Dental Hospital | 2 | 1 |
| Seoul National University Gwanak Dental Hospital | 1 | 1 |
Disease areas (700)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 115 |
| Diabetes Mellitus | 84 |
| Coronary Disease | 81 |
| Liver Neoplasms | 76 |
| Coronary Artery Disease | 72 |
Showing 5 of 700 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2024 | 9 |
| 2023 | 9 |
| 2022 | 3 |
| 2021 | 7 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 5 |
| 2016 | 4 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (16)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Immune Checkpoint Inhibitors | Carcinoma, Non-Small-Cell Lung | Not reported | 1 |
| Immune Checkpoint Inhibitors | Lung Neoplasms | Not reported | 1 |
| Corticosteroids | Carcinoma, Non-Small-Cell Lung | Not reported | 1 |
| Corticosteroids | Lung Neoplasms | Not reported | 1 |
| Muco-active agents | Disease | Not reported | 1 |
Showing 5 of 16 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| METHYLPHENIDATE | 1 |
| Escitalopram | 1 |
| BOTULINUM TOXIN TYPE-A | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 55% hit target (n=11) | 50% on time (n=10) |
Journals published in (1,073)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 98 |
| British journal of anaesthesia | 72 |
| Anesthesiology | 71 |
| Anesthesia and analgesia | 56 |
| Circulation | 55 |
Showing 5 of 1,073 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 69 | 41 | 2025-12-23 |
Organization relationships (254)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Yonsei University | Co sponsors trial with | 85 |
| Samsung (South Korea) | Co sponsors trial with | 74 |
| Asan Foundation | Co sponsors trial with | 70 |
| Korea University | Co sponsors trial with | 37 |
| Hanyang University | Co sponsors trial with | 36 |
Showing 5 of 254 relationships.
Latest dated events (2,654)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 2,654 events.
Biomarker capability evidence (10)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| ERBB2 | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial inclusion criteria |
| MS4A1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 10 evidence rows.
Biomarkers this organization publishes on (1,480)
Shown in this order: most publications first.
Showing 5 of 1,480 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.